The suppressive binding of VISTA to PSGL-1 in acidic conditions may be a potential tumor evasion strategy, highlighting both a new role for PSGL-1 in tumors and the possibility of targeting PSGL-1 and/or VISTA for future cancer immunotherapies. Here, VSIR is linked to cancer.